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ABSTRACT  
Somatosensation is divided into proprioception and cutaneous sensation. Dorsal root ganglion 
(DRG) neurons project their fibers toward peripheral targets including muscles and skin, and 
centrally to the spinal cord. Proprioceptive DRG neurons transmit information from muscle 
spindles and Golgi tendon organs to the spinal cord. We previously showed that Runt-related 
transcription factor 3 (Runx3) is expressed in these neurons and their projections to the ventral 
spinal cord and muscle spindles are lost in Runx3-deficient (Runx3-/-) mouse embryos. Although 
Runx3 is likely to contribute to the fate decision and projection of proprioceptive DRG neurons, 
the precise roles for Runx3 in these phenomena are unknown. To identify genes regulated by 
Runx3 in embryonic DRGs, we performed microarray analyses using cDNAs isolated from 
wild-type and Runx3-/- DRGs of embryonic day (E) 12.5 and selected two transcript variants of 
the tyrosine kinase receptor C (TrkC) gene. These variants, Ntrk3 variant 1 (Ntrk3-v1) and 
variant 2 (Ntrk3-v2), encode full-length and truncated receptors of neurotrophin-3, respectively. 
Using double in situ hybridization, we found that most of Ntrk3-v1 mRNA expression in E14.5 
DRGs depended on Runx3 but that more than half of Ntrk3-v2 mRNA one were expressed in a 
Runx3-independent manner. Furthermore, our data revealed that the rate of Ntrk3-v1 and 
Ntrk3-v2 colocalization in DRGs changed from E14.5 to E18.5. Together, our data suggest that 
Runx3 may play a crucial role in the development of DRGs by regulating the expression of 
Ntrk3 variants and that DRG neurons expressing Ntrk3-v1 but not Ntrk3-v2 may differentiate 
into proprioceptive ones.  
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INTRODUCTION 
  
Runt-related transcription factors (Runx) are characterized by their Runt domains. In mammals, 
they are subdivided into three subfamilies, that is, Runx1, 2, and 3 (Levanon and Groner, 2004; 
Inoue et al., 2008; Ito, 2008). Runx1 is involved in the differentiation of blood cells and is 
known as a causative gene of acute myeloid leukemia (Okuda et al., 1996; Ito, 2008; Ichikawa 
et al., 2013). Runx2 is essential for bone formation and acts as a causative gene for cleidocranial 
dysplasia (Komori et al., 1997; Otto et al., 1997; Ito, 2008). Runx3 is expressed in the 
gastrointestinal mucosa epithelium and has been shown to act as a tumor suppressor gene in the 
gastric cancer (Li et al., 2002; Ito, 2008). In addition, both Runx1 and 3 are expressed in the 
nervous system, especially in dorsal root ganglion (DRG) neurons at early stages of 
development. They play a pivotal role in the formation of subtypes and projections of DRG 
neurons (Inoue et al., 2002, 2008; Levanon et al., 2002; Chen et al., 2006a; Chen et al., 2006b; 
Kramer et al., 2006; Yoshikawa et al., 2007, 2013; Nakamura et al., 2008; Lallemend et al., 
2012; Yang et al., 2013).  
DRG neurons are responsible for the transmission of somatic information that is classified 
into nociception, mechanoreception, and proprioception. Nociceptive and mechanoreceptive 
DRG neurons project their fibers to the dorsal horn of the spinal cord and to the skin. 
Nociceptive DRG neurons express receptors for neurotrophic factors such as tyrosine kinase 
receptor A (TrkA) and Ret. Mechanoreceptive DRG neurons express various receptors for 
neurotrophic factors such as TrkB, TrkC, GDNF family receptor α1-4 (GFRα1-4), and Ret 
(Inoue et al., 2002; Luo et al., 2009; Honma et al., 2010; Abdo et al., 2011; Lallemend and 
Ernfors, 2012; Yoshikawa et al., 2013). Conversely, proprioceptive DRG neurons express TrkC 
and project their fibers to the ventral horn and intermediate zone of the spinal cord, Golgi 
tendon organs and to muscle spindles, transmitting the information necessary for coordinated 
movement, such as tension of the muscle and the position of the limbs (Inoue et al., 2002; 
Lallemend and Ernfors, 2012). Previous studies showed that nonpeptidergic nociceptive DRG 
neurons express Runx1 and that proprioceptive DRG neurons express Runx3 (Levanon et al., 
2002; Kramer et al., 2006; Yoshikawa et al., 2007; Inoue et al., 2008; Lallemend and Ernfors, 
2012).  
The role of Runx3 in DRG neuronal development has been analyzed by studying mouse 
embryos deficient for the Runx3 gene (Runx3-/-). Several studies have revealed that Runx3-/- 
embryos have deficiencies in the projections of their proprioceptive DRG neurons to both 
peripheral and central targets (Inoue et al., 2002; Levanon et al., 2002). More recently, by 
analyses using double knockout mouse embryos deficient for Bax and Runx3 genes, the 
defective projections of proprioceptive DRG neurons are not due to cell death, but due to 
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changes in the fate of DRG neurons (Nakamura et al., 2008; Lallemend et al., 2012). 
Proprioceptive DRG neurons differentiate from precursor neurons coexpressing TrkC and TrkB, 
and Runx3 is involved in this differentiation (Kramer et al., 2006; Inoue et al., 2008). After 
embryonic day (E) 11.5, the precursor neurons coexpressing TrkC and TrkB are suppressed in 
their TrkB expression by Runx3 and they differentiate into TrkC-positive/TrkB-negative 
proprioceptive DRG neurons (Kramer et al., 2006; Inoue et al., 2007; Abdo et al., 2011). The 
fate of proprioceptive DRG neurons is likely to be converted into that of mechanoreceptive 
DRG neurons in Runx3-/- mouse embryos and the projection of the proprioceptive fibers thus 
might be lost in these embryos. However, the expression of the TrkC protein is partly 
maintained in Runx3-/- mouse DRGs (Nakamura et al., 2008). This observation led us to identify 
genes that contribute to the fate and projection of proprioceptive DRG neurons in the 
downstream of Runx3.  
In this study, as a first step to elucidate the Runx3-regulated mechanism that controls the cell 
fate and projection of proprioceptive DRG neurons, we examined the expression pattern of 
downstream genes of Runx3 in DRG neurons. We found that Runx3 is involved in the 
development of DRG neurons by regulating the expression of two transcript variants of the 
TrkC gene.  
 
 
MATERIALS AND METHODS 
 
Animals 
The generation and characterization of Runx3-deficient mice were performed as described 
previously (Inoue et al., 2002). Noon of the vaginal plug date was considered as embryonic day 
0.5 (E0.5). After anesthetic treatment with isoflurane, E12.5-18.5 mouse embryos were excised. 
Genotyping was performed by polymerase chain reactions (PCRs) using primer pairs as 
described previously (Nakamura et al., 2008). All experiments using mice were performed 
according to the Guide for the Care and Use of Laboratory Animals of the University of 
Tsukuba.  
 
Microarray Analysis 
From E12.5 wild-type and Runx3-/- mouse embryos, DRGs (from cervical to lumbar levels) 
were dissected, and the samples were analyzed by use of an Agilent Expression Array (Agilent 
Technologies, California). Log2 ratios representing the difference in the expression level were 
obtained on the basis of the expression level in wild-type mouse DRGs.  
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In Situ Hybridization 
In vitro transcription from the cDNA fragments of mouse Neurotrophic tyrosine kinase receptor 
type3 variant 1 (Ntrk3-v1, NM_008746, 1977-2638; 662 bp), mouse Neurotrophic tyrosine 
kinase receptor type3 variant 2 (Ntrk3-v2, NM_182809, 1686-2713; 1028 bp), and mouse 
Runx3 (NM_019732, 944-1938; 995 bp, Usui et al., 2012) was performed with a digoxigenin 
(DIG) or fluorescein (FLU) RNA labeling kit (Roche Diagnostics, Basel, Switzerland). Lumbar 
segments 1 and 2 of E14.5 wild-type or Runx3-/- mouse embryos were dissected out and frozen 
in Tissue-Tek OCT compound (Sakura Finetech Japan, Tokyo, Japan). Transverse sections 
(10-µm thickness) were cut using a cryostat and collected onto silane-coated glass slides. 
(Agilent Technologies). After fixation with paraformaldehyde / 0.1 M phosphate buffer for 10 
min, the sections were dehydrated with 100% methanol for 1 h and acetylated with 
triethanolamine (Sigma-Aldrich, Missouri, USA) for 10 minutes. Hybridization was carried out 
for 18 h at 72oC with DIG-labeled cRNA probes (500 ng/ml). Prior to detection, sections were 
washed in 2 × SSC for 1 h at 72oC and for 30 min at room temperature. After incubation with 
normal goat serum (Vector Laboratories, Peterborough, UK) for 2 h at room temperature, 
hybridization was detected by treatment with sheep anti-DIG-AP, fab fragments (Roche 
Diagnostics, 1 : 10,000), sheep anti-FLU-AP, fab fragments (Roche Diagnostics; 1 : 10,000), 
sheep anti-DIG-POD, fab fragments (Roche Diagnostics; 1 : 1000), or sheep anti-FLU-POD, 
fab fragments (Roche Diagnostics; 1 : 1000) for 2 days at 4oC. To detect alkaline phosphatase, 
we used the 2-hydroxy-3-naphthoic acid-2'-phenylanilide phosphate (HNPP) Fluorescent 
Detection Set (Roche Diagnostics). To detect peroxidase, we used the TSA Plus Cyanine 3 
System (PerkinElmer, Massachusetts; 1:100) or TSA Plus Biotin Kit (PerkinElmer; 1:100) and 
Alexa Fluor 488-labeled streptavidin (Life Technologies, California; 1:1000). To calculate the 
ratio of positive cells, we obtained the total number of DRG neurons by Islet-1/2 staining 
described below and then calculated the percentage of various mRNA-expressing cells among 
the total number of DRG neurons per section. Data were statistically analyzed using Student’s 
unpaired t-test.  
 
Immunohistochemistry 
After in situ hybridization, sections were incubated with a rat monoclonal antibody against 
Islet-1/2 (39.4D5, Developmental Studies Hybridoma Bank, Iowa; 1:200) overnight at 4oC. 
Then, they were incubated with an Alexa Fluor 488-labeled goat anti-mouse IgG antibody (Life 
Technologies; 1:1000) at room temperature for 1 h. The sections were sealed with 
VECTASHIELD Mounting Medium with 4',6-diamidino-2-phenylindole (DAPI, Vector 
Laboratories) and photographed using an AxioVision (Carl Zeiss, Jena, Germany).  
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Real-Time Quantitative Reverse Transcription PCR 
Total RNA was prepared from DRGs of E14.5 wild-type and Runx3−/− mouse embryos from 
thoracic to lumbar levels using an RNeasy Plus Micro Kit (Qiagen, Limburg, Netherlands). The 
cDNA was synthesized using a QuantiTect Reverse Transcription Kit (Qiagen). Using SYBR 
Premix Ex Taq II (Takara Bio, Shiga, Japan), real-time quantitative reverse transcription PCR 
(qRT-PCR) was carried out for 50 cycles by Thermal Cycler Dice Real Time System (TP800; 
Takara Bio). All of the reactions were conducted in duplicate for each cDNA sample and four 
animals from each genotype were used. The following PCR primers were used: Ntrk3-v1 
forward, 5′-TGGTCTTTGAATACATGAAGCATGG-3′, reverse, 
5′-AGGCTATCTGACTGGCGATGTG-3′ (amplicon size, 150 bp; Takara Bio); Ntrk3-v2, 
forward, 5′-GAACCTTTGGAACCCAGTGGAA-3′, reverse, 
5′-CACACATATTGACCAGAGACCAGGA-3′ (amplicon size; 138 bp; Takara Bio); 18S rRNA, 
forward, 5′-ACTCAACACGGGAAACCTCA-3′, reverse, 
5′-AACCAGACAAATCGCTCCAC-3′ (Hokkaido System Science Co, Hokkaido, Japan). The 
18S rRNA expression level was determined for each sample to normalize the data. Data were 
statistically analyzed by use of Student’s unpaired t-test.  
 
 
RESULTS 
 
Selection of Candidate Genes that Contribute to the Cell Fate Decision and Projection of 
DRG Neurons 
Microarray analyses were performed using DRGs from E12.5 wild-type (n = 15) and Runx3-/- (n 
= 15) mouse embryos. Based on previous studies on neural development, we obtained more 
than 20 genes that showed a difference in expression amount more than twice between 
wild-type and Runx3-/- mouse DRGs (Table 1). We then focused on two Ntrk3 genes encoding 
the TrkC receptor for neurotrophic factor neurotrophin-3 (NT3; Table 1). Neurotrophic tyrosine 
kinase receptor type3 variant 1 (Ntrk3-v1, NCBI Reference Sequence: NM_008746) and 
Neurotrophic tyrosine kinase receptor type3 variant 2 (Ntrk3-v2, NCBI Reference Sequence: 
NM_182809) are transcript variants of Ntrk3 genes. The results of these microarray analyses 
showed that the relative expression values (log2 ratios) of Ntrk3-v1 in Runx3-/- mouse DRGs 
were –2.71 and that those of Ntrk3-v2 were –1.26 compared with the wild-type values (Table 1). 
Previous experiments have revealed that NT3 acts as a chemoattractant for DRG neurites in 
vitro and is required for the innervation of TrkC-positive DRG fibers toward their targets in vivo 
(Genç et al., 2004; Usui et al., 2012). These results clearly suggest that the NT3/TrkC signaling 
pathway may be involved in the projection of proprioceptive DRG neurons. Although both of 
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the cDNA sequences maintain a homology from extracellular to transmembrane domains, the 
sequences of their intracellular ones are different (Supporting Information Fig. 1; Menn et al., 
1998). The Ntrk3-v1 gene has a tyrosine kinase domain, whereas the Ntrk3-v2 gene lacks this 
domain. Thus, Ntrk3-v1 and Ntrk-v2 proteins are considered to be a full-length TrkC with 
tyrosine kinase activity (full-length TrkC) and an incomplete TrkC (truncated TrkC), 
respectively (Ichinose and Snider, 2000; Cronk et al., 2002).  
 
Expression of Ntrk3 mRNAs Regulated by Runx3 
By performing in situ hybridization using specific cRNA probes for Ntrk3-v1 and Ntrk3-v2, we 
examined the Ntrk3-v1 and Ntrk3-v2 mRNA expression profiles in E14.5 wild-type and Runx3-/- 
DRGs (Fig. 1A–D). In these experiments, we used FLU-labeled cRNA probes to detect both 
Ntrk3-v1 and Ntrk3-v2 signals. Islet-1/2, a marker of pan-DRG neurons, was seen in the nucleus 
of DRG neurons, whereas Ntrk3-v1 and Ntrk3-v2 were expressed in the cytoplasm and the 
nucleus, respectively (Fig. 1A–D). We confirmed that several other cRNA probes for Ntrk3-v1 
and Ntrk3-v2 (probes synthesized against other gene regions of Ntrk3-v1 and Ntrk3-v2) also 
showed the same expression patterns in the cytoplasm and the nucleus (data not shown). The 
percentage of Ntrk3-v1 and Ntrk3-v2 mRNA-positive DRG neurons among neurons expressing 
Islet-1/2 was calculated for both wild-type and Runx3-/- DRGs. We observed that 5.98 and 
0.34% of DRG neurons expressed Ntrk3-v1 mRNA in E14.5 wild-type and Runx3-/- DRGs, 
respectively (Fig. 1A, B, E). Conversely, Ntrk3-v2-positive neurons were observed with 5.45% 
in E14.5 wild-type DRGs, and with 3.21% in Runx3-/- ones (Fig. 1C–E). Therefore, the 
percentage rates of Ntrk3-v1- and Ntrk3-v2-positive neurons among total DRG neurons in 
Runx3-/- embryos as compared with those for wild-type ones were 5.7% and 58.8%, respectively. 
Additionally, using qRT-PCR we performed rate-of-change analyses of the expression of 
Ntrk3-v1 and Ntrk3-v2 mRNAs in DRG neurons under Runx3 deficiency and confirmed that 
Ntrk3-v1 and Ntrk3-v2 expression levels in Runx3-/- DRGs showed a significant reduction 
compared with those in wild-type ones, although the degree of reduction in the level of Ntrk3-v2 
mRNA was smaller than that in Ntrk3-v1 mRNA (Supporting Information Fig. 2A–C). Together, 
these results suggest that most of the Ntrk3-v1 mRNA expression in E14.5 DRGs depended on 
Runx3 and that more than half of the Ntrk3-v2 mRNA expression was independent of Runx3 in 
these neurons.  
 
Colocalization of Ntrk3-v1 and Ntrk3-v2 mRNAs in DRG Neurons 
Next, we examined the colocalization of Ntrk3-v1 and Ntrk3-v2 using a double in situ 
hybridization procedure. To detect Ntrk3-v1 and Ntrk3-v2 signals, we used FLU- and 
DIG-labeled cRNA probes, respectively. Ntrk3-v1 was expressed in the cytoplasm of DRG 
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neurons, whereas Ntrk3-v2 and DAPI were seen in the nucleus (Fig. 2A–H). We observed that 
63.1% of Ntrk3-v1 mRNA-positive DRG neurons coexpressed Ntrk3-v2 mRNA and that 67.6% 
of Ntrk3-v2 mRNA-positive DRG neurons coexpressed Ntrk3-v1 mRNA in E14.5 wild-type 
embryos (Fig. 2A–D, I, J). To further characterize Ntrk3-v2 and Ntrk3-v1 colocalization at later 
development, we examined the colocalization of Ntrk3-v1 and Ntrk3-v2 mRNA-positive DRG 
neurons in wild-type DRGs at E18.5 when proprioceptive DRG neurons have finished their 
projection to the ventral horn of the spinal cord. We observed that 89.1% of Ntrk3-v2 
mRNA-positive DRG neurons coexpressed Ntrk3-v1 mRNA and 43.5% of Ntrk3-v1 
mRNA-positive DRG neurons coexpressed Ntrk3-v2 mRNA in E18.5 wild-type embryos (Fig. 
2E–I, K). These results showed that the colocalization rate of Ntrk3-v1 and Ntrk3-v2 mRNAs in 
DRG neurons had changed from E14.5 to E18.5.  
 
Colocalization of Ntrk3s mRNA and Runx3 mRNA in DRG Neurons 
Using the double in situ hybridization procedure, we also examined the colocalization of 
Ntrk3-v1 or Ntrk3-v2 with Runx3 in E14.5 wild-type DRGs. To detect Runx3 signals, we used 
the FLU-labeled cRNA probe; and for detection of Ntrk3-v1 and Ntrk3-v2 signals, DIG-labeled 
cRNA probes. We observed that 92.0% of Ntrk3-v1 mRNA-positive DRG neurons and 53.8% of 
Ntrk3-v2 mRNA-positive ones coexpressed Runx3 mRNA (Fig. 3A–D, I–L, Q, R). These results 
showed that the rate of colocalization of Ntrk3-v1 and Runx3 in E14.5 wild-type DRGs was 
nearly equal to the reduction rate of Ntrk3-v1-positive neurons in E14.5 Runx3-/- ones (Fig. 1E). 
These results further showed that the rate of colocalization of Ntrk3-v2 and Runx3 in wild-type 
DRGs was also equal to the reduction rate of Ntrk3-v2-positive neurons in Runx3-/- mouse ones 
at E14.5 (Fig. 1E). Next, we examined the colocalization of Ntrk3-v1 or Ntrk3-v2 with Runx3 in 
E18.5 wild-type DRGs and found that 46.2% of Ntrk3-v1 mRNA-positive DRG neurons and 
24.0% of Ntrk3-v2 mRNA-positive DRG neurons coexpressed Runx3 (Fig. 3E–H, M–Q, S). 
These results showed that the colocalization rates of Ntrk3-v1 or Ntrk3-v2 with Runx3 in DRGs 
changed from E14.5 to E18.5. In other words, our results revealed that the rate of Ntrk3-v2 
mRNA-positive and Runx3-negative DRG neurons increased at E18.5 and that 
Ntrk3-v1-positive and Runx3-negative DRG neurons emerged at the same stage.  
 
 
DISCUSSION 
 
In this study, as a first step to search for molecules that control the cell fate and projection of 
proprioceptive DRG neurons in the downstream of Runx3, we examined the expression of two 
transcript variants of the TrkC gene, Ntrk3-v1 and Ntrk3-v2. In mouse embryonic DRG neurons, 
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we examined whether the expression of Ntrk3-v1 and Ntrk3-v2 depended on Runx3 or not. At 
E14.5, corresponding to the period when proprioceptive DRG fibers project to the intermediate 
zone, Ntrk3-v1 expression in Runx3-/- DRGs was low, whereas more than half of the Ntrk3-v2 
expression was observed in these DRGs in a Runx3-independent manner. Thus, these results 
suggest that the development of DRG neurons may be controlled through the Runx3-regulated 
expression of TrkC transcript variants.  
 
Projection of Proprioceptive DRG Neurons Regulated by Runx3 
Proprioceptive DRG neurons have been reported to use TrkC for responding to NT3-induced 
chemoattraction and extend their fibers to the muscle spindle and ventral horn of the spinal cord 
expressing NT3 (Fariñas et al., 1996; Chen et al., 2002). This axonal guidance mechanism is 
based on the observation that projections of proprioceptive DRG fibers to the ventral horn are 
lost in both NT3-/- and Ntrk3-/- embryos (Ernfors et al., 1994; Patel et al., 2003; Genç et al., 
2004; Usui et al., 2012). We previously examined the developmental patterns of all TrkC 
expression including Ntrk3-v1 and Ntrk3-v2 using anti-TrkC antibody (antibody against the 
extracellular domain of TrkC). In Runx3-/- mouse embryos, in spite of the loss of proprioceptive 
DRG neurons, TrkC-expressing neurons are not completely lost, indicating that TrkC expression 
is partially maintained even in Runx3-/- mouse DRGs (Nakamura et al., 2008). From these 
results, it is quite difficult to explain the mechanism of the projection of proprioceptive DRG 
neurons by only the NT3/TrkC signaling pathway. The Ntrk3-v2 receptor without tyrosine 
kinase activity (truncated TrkC) is considered to be dominant-negative for the Ntrk3-v1 receptor 
with tyrosine kinase activity (full-length TrkC; Palko et al., 1999). Conversely, it is highly 
possible that the NT3/Ntrk3-v2 signaling has functions different from those of the 
NT3/Ntrk3-v1 signaling, because Ichinose and Snider (2000) showed that the total length of 
neurite outgrowth is maintained in Ntrk3-v2-transfected wild-type DRG neurons but that their 
outgrowth patterns are different from those of Ntrk3-v1-transfected ones. Furthermore, knockout 
mice for the entire extracellular domain of TrkC, which lack the functions of both Ntrk3-v1 and 
Ntrk3-v2, exhibit more serious abnormalities in the development of Merkel cells and projections 
of mechanoreceptive DRG neurons to Merkel cells than those in Ntrk3-v1-deficient mice 
lacking the tyrosine kinase domain of TrkC. These results suggest a different function of 
Ntrk3-v2 in the projection of mechanoreceptive DRG neurons (Cronk et al., 2002).  
In the present results obtained by in situ hybridization, the expression of Ntrk3-v1 was almost 
lost, but that of Ntrk3-v2 was seen, in E14.5 Runx3-/- DRG neurons (Fig. 1E). Thus, at E14.5, 
corresponding to the stage of intensive axonal projection, the Ntrk3-v1 protein may be 
expressed in a Runx3-dependent manner in proprioceptive DRG neurons, but Ntrk3-v2, in a 
Runx3-independent manner in presumptive mechanoreceptive DRG neurons. Therefore, fibers 
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of proprioceptive DRG neurons may be guided toward the ventral horn of the spinal cord via the 
NT3/Ntrk3-v1 signaling pathway under the control of Runx3. Knockdown experiments for 
Ntrk3-v1 in wild-type DRG neurons or rescue experiments for Ntrk3-v1 in Runx3-/- DRG 
neurons may further reveal the precise role for Ntrk3-v1 in the projection of proprioceptive 
DRG neurons.  
 
Transition of Colocalization of Ntrk3s and Runx3 in Embryonic DRG Neurons 
Our study showed that Ntrk3-v1 and Ntrk3-v2 exhibited different expression patterns in 
colocalization with Runx3. Whereas the majority of Ntrk3-v1 colocalized with Runx3 in E14.5 
wild-type DRG neurons, about half of Ntrk3-v2 did not colocalize with Runx3 (Fig. 3Q, R). This 
result is consistent with the fact that more than half of the Ntrk3-v2-positive DRG neurons were 
present in E14.5 Runx3-/- mouse embryos (Fig. 1E). Furthermore, our study revealed that almost 
all Runx3- and Ntrk3-v2-double-positive DRG neurons coexpressed Ntrk3-v1 at E14.5 (Fig. 3R). 
Taken together, these results suggest that the subpopulation of Ntrk3-v2-positive DRG neurons 
lost in Runx3-/- embryos might be proprioceptive DRG neurons coexpressing Runx3 and 
Ntrk3-v1 and that another subpopulation, which was not lost in Runx3-/- embryos, might be 
mechanoreceptive DRG neurons. In addition, the colocalization of Ntrk3-v1 or Ntrk3-v2 with 
Runx3 showed a different pattern between E14.5 and E18.5. In particular, about half of the 
Ntrk3-v1-positive DRG neurons did not express Runx3 at E18.5 (Fig. 3S). These results imply 
that the Ntrk3-v1 expression may be regulated by Runx3 in a stage-specific manner.  
What type of neurons coexpress Ntrk3-v1 and Ntrk3-v2 in each stage? Furthermore, what 
function do Ntrk3-v1 and Ntrk3-v2 have in each stage? TrkB, a receptor for brain-derived 
neurotrophic receptor (BDNF), is present as two isoforms, full-length TrkB (TrkB.tk+) and 
truncated TrkB (TrkB.t1; Fenner, 2012). On the basis of these isoforms, three types of dimers, 
TrkB.tk+ homodimers, TrkB.t1 homodimers, and TrkB.t1-TrkB.tk+ heterodimers, are present in 
the brain (Fenner, 2012). TrkB.t1 homodimers are known to regulate the concentration of 
extracellular BDNF, change the morphology of neurons and glial cells, and activate the 
intracellular signaling (Fenner, 2012). Conversely, TrkB.t1-TrkB.tk+ heterodimers have a 
dominant-negative function to inhibit the action of the TrkB.tk+ signaling (Fenner, 2012). In the 
case of TrkC, it is not yet clear whether Ntrk3-v1 and Ntrk3-v2 form a heterodimer as in the 
case of TrkB, but it is highly possible that Ntrk3-v2 forms a heterodimer with Ntrk3-v1 and 
functions as a dominant-negative receptor. Because most of the Ntrk3-v1- and 
Ntrk3-v2-double-positive neurons coexpressed Runx3 at E14.5, they were supposedly 
proprioceptive DRG neurons. However, most of these double-positive neurons did not 
coexpress Runx3 at E18.5, suggesting that they might not be proprioceptive DRG neurons. At 
E18.5, DRG neurons have almost completed their projections to the targets and begun synapse 
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formation (Mears and Frank, 1997; Ozaki and Snider, 1997). We cannot exclude the possibility 
that colocalization of Ntrk3-v1 and Ntrk3-v2 may be involved in the synapse formation of DRG 
neurons.  
It is well known that hierarchical transcription factors are used to specify DRG sensory 
neurons. Although the expression of Ntrk3-v1 and Ntrk3-v2 may be controlled by Runx3, it is 
unclear whether Runx3 binds directly to the regulatory region of the Ntrk3 gene or acts through 
some other transcription factors. Further studies will clarify this issue.  
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Figure legends 
 
Figure 1 
Rates of Ntrk3-v1 and Ntrk3-v2 mRNA-positive cells in Runx3-/- and wild-type DRG neurons. 
(A, B) Fluorescent double-stained images of Ntrk3-v1 mRNA (red) and Islet-1/2 protein (green) 
at E14.5 for wild-type (A) and Runx3-/- (B) DRGs of lumbar segments 1 and 2 (L1-2). 
Horizontal cross-sectioned slices of the DRG are shown. Insets show enlarged views of the 
areas surrounded by the white square. (C, D) Fluorescent double-stained images of Ntrk3-v2 
mRNA (red) and Islet-1/2 protein (green) at E14.5 wild-type (A) and Runx3-/- (B) L1-2 DRGs. 
Horizontal cross-sectioned slices of the DRG are shown. Insets show enlarged views of the 
areas surrounded by the white square. (E) Quantification of Ntrk3-v1 and Ntrk3-v2 
mRNA-positive DRG neurons in E14.5 wild-type (black bars; 15 sections for counting 
Ntrk3-v1-positive neurons, 20 sections for counting Ntrk3-v2-positive neurons) and Runx3-/- 
mouse embryos (white bars; 15 sections for counting Ntrk3-v1-positive neurons, 15 sections for 
counting Ntrk3-v2-positive neurons). The bars represent the means + SEM. *p < 0.01, **p < 
0.0001. Scale bars: 50 µm.  
 
Figure 2 
Colocalization of Ntrk3-v1 and Ntrk3-v2 mRNAs in DRG neurons. (A–D) Triple-stained images 
of Ntrk3-v1 mRNA (A; red), Ntrk3-v2 mRNA (B; green), and DAPI (C; blue) in DRGs of 
lumbar segments 1 and 2 of E14.5 wild-type mouse embryos. Horizontal cross-sectioned slices 
of the DRG are shown. Dashed lines indicate the outer edge of the DRG, and insets show 
enlarged views of the areas surrounded by the white square. Scale bar: 50 μm. (E–H) Same 
images at E18.5. Scale bar: 50 μm. (I) Graph showing the ratio of the number of Ntrk3-v1 and 
Ntrk3-v2 mRNA coexpressing cells compared with that of Ntrk3-v1 or Ntrk3-v2 mRNA-positive 
cells in E14.5 (black bars; 14 sections) and E18.5 (white bars; 8 sections) wild-type DRGs. The 
bars represent the means + SEM. (J) Diagram showing the coexpression pattern of Ntrk3-v1 and 
Ntrk3-v2 mRNAs in E14.5 wild-type DRGs. (K) Same diagram for E18.5 wild-type DRGs.  
 
Figure 3 
Colocalization of Ntrk3-v1 or Ntrk3-v2 mRNA with Runx3 mRNA in DRG neurons. (A–D) 
Triple-stained images of Runx3 mRNA (A; red), Ntrk3-v1 mRNA (B; green), and DAPI (C; 
blue) in DRGs of lumbar segments 1 and 2 (L1-2) of E14.5 wild-type embryos. Horizontal 
cross-sectioned slices of the DRG are shown. Dashed lines indicate the outer edge of the DRG, 
and the inset shows an enlarged view of the area surrounded by the white square. Scale bar: 50 
μm. (E–H) Same images for E18.5 wild-type embryos. Scale bar: 100 μm. (I–L) Triple-stained 
16 
images of Runx3 mRNA (I; red), Ntrk3-v2 mRNA (J; green), and DAPI (K; blue) in L1-2 DRGs 
of E14.5 wild-type embryos. Horizontal cross-sectioned slices of the DRG are shown. Dashed 
lines indicate the outer edge of the DRG, and insets show enlarged views of the areas 
surrounded by the white square. Scale bar: 50 μm. (M–P) Same images for E18.5 wild-type 
embryos. Scale bar: 100 μm. (Q) Graph showing the ratio of the number of Ntrk3-v1 or 
Ntrk3-v2 mRNA-positive cells coexpressing Runx3 compared with that of Ntrk3-v1 or Ntrk3-v2 
mRNA-positive cells in E14.5 (black bars; 15 sections for counting Runx3- and/or 
Ntrk3-v1-positive neurons, 14 sections for counting Runx3- and/or Ntrk3-v2-positive neurons) 
and E18.5 (white bars; 9 sections for counting Runx3- and/or Ntrk3-v1-positive neurons, 10 
sections for counting Runx3- and/or Ntrk3-v2-positive neurons) wild-type DRGs. The bars 
represent the means + SEM. (R) Diagram showing the coexpression pattern of Ntrk3-v1, 
Ntrk3-v2, and Runx3 mRNAs in E14.5 wild-type DRGs. (S) Same diagram for E18.5 wild-type 
DRGs.  
Supporting Information Figure 1 
Schematic diagram of Ntrk3-v1 and Ntrk3-v2 transcripts. Extracellular domain (EC), 
transmembrane domain (TM), tyrosine kinase domain (TK), non-catalytic 2 domain (NC2).  
Supporting Information Figure 2 
Regulation of the expression of Ntrk3-v1 and Ntrk3-v2 mRNAs by Runx3. (A) Amplification 
plots of qRT-PCR for Ntrk3-v1 mRNA levels in E14.5 wild-type (orange curves) and Runx3-/- 
(blue curves) DRGs. (B) Amplification plots of qRT-PCR for Ntrk3-v2 mRNA levels in E14.5 
wild-type (red curves) and Runx3-/- (blue curves) DRGs. (C) The expression levels of Ntrk3-v1 
and Ntrk3-v2 mRNAs were compared between the wild-type (black bars, n = 2) and Runx3-/- 
(white bars, n = 3) DRGs at E14.5, as determined by qRT-PCR. The bars represent the means + 
SEM. *p < 0.05, **p < 0.01.  
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